Conditions: Central Serous Chorioretinopathy
Keywords: Persistent Central Serous Chorioretinopathy Regeneron CSR CSCR
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 12
Healthy volunteers: no

Brief summary:
A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.

Detailed description:
Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study

Arms:
arm 1: 2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times). arm 2: 2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).

Interventions: intervention 1: Intravitreal Aflibercept Injection
Intervention descriptions: intervention 1: GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).

GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total).

Protocol document: